BellBrook Therapeutics

Targeting enzymes critical to disease pathobiology in interferon-driven autoimmune diseases, cancer, and liver fibrosis

ABOUT BELLBROOK

Since commercialization of the first Transcreener HTS assays in 2006, we have worked closely with outstanding scientists in pharma, biotech and academic laboratories, sharing in our clients’ drug discovery successes and failures for more than 10 years. In 2015, we began to use our accumulated expertise, combined with some of our most enabling assay methods to pursue targets with very high therapeutic potential that remained unaddressed because of technical hurdles.  We are working with some outstanding partners for medicinal chemistry, computational chemistry and translational research, and we are doing what we are best at: using innovative biochemical and cellular tools to extract accurate information about the interplay between chemistry and biology.

Bellbrook Timeline

GTPases such as Ras act as molecular switches to transduce signals from cell surface receptors into pathways regulating cell growth, morphology and movement; their aberrant activation leads to tumorigenesis and invasion. Despite their central role in diseases like cancer and fibrosis, development of drugs that target GTPases has eluded scientists for decades. BellBrook is using proprietary assay technology to discover small molecules that modulate GTPases indirectly, by inhibiting the proteins that control their activation state.  

The cGAS/STING pathway activates the immune system in response to foreign and/or damage induced self-DNA. Aberrant activation of cGAS by self-DNA contributes to debilitating and sometimes fatal autoimmune diseases. BellBrook is using a proprietary cGAS enzymatic assay to discover cGAS inhibitors for treatment of rare, monogenic autoimmune diseases and systemic lupus erythematosus (SLE).